Galmed Pharmaceuticals Holds Shareholder Meeting
Ticker: GLMD · Form: 6-K · Filed: Oct 21, 2024 · CIK: 1595353
| Field | Detail |
|---|---|
| Company | Galmed Pharmaceuticals LTD. (GLMD) |
| Form Type | 6-K |
| Filed Date | Oct 21, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $10.0 million, $20.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, filing-update
TL;DR
Galmed Pharma held a shareholder meeting on Oct 21 to vote on a proposal from a Sept 20 proxy.
AI Summary
On October 21, 2024, Galmed Pharmaceuticals Ltd. held a Special General Meeting of Shareholders where shareholders voted on a proposal previously detailed in a proxy statement filed on September 20, 2024. The specific outcome of this vote is not detailed in this filing.
Why It Matters
Shareholder meetings are crucial for corporate governance, allowing investors to vote on important company matters and influence strategic direction.
Risk Assessment
Risk Level: low — This filing is a routine report of a shareholder meeting and does not contain new financial or operational information that would significantly alter risk.
Key Players & Entities
- Galmed Pharmaceuticals Ltd. (company) — Registrant
- October 21, 2024 (date) — Date of Special General Meeting of Shareholders
- September 20, 2024 (date) — Date of proxy statement filing
FAQ
What was the specific proposal voted on at the Special General Meeting of Shareholders?
The filing states that shareholders voted on the proposal described in the proxy statement for the Meeting, which was included as an exhibit to the Company's Form 6-K filed on September 20, 2024. However, the details of the proposal itself are not reiterated in this document.
When was the proxy statement for the meeting filed?
The proxy statement was filed on September 20, 2024.
What is the company's central index key?
The company's central index key is 0001595353.
What is the company's SEC file number?
The company's SEC file number is 001-36345.
Does Galmed Pharmaceuticals file annual reports under Form 20-F or 40-F?
Galmed Pharmaceuticals indicates it files annual reports under Form 20-F.
Filing Stats: 469 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-10-21 16:16:01
Key Financial Figures
- $10.0 million — rrence, an “Advance”) up to $10.0 million (the “Commitment Amount”) o
- $20.0 million — ;) to increase the Commitment Amount to $20.0 million of the Company’s Ordinary Shares.
Filing Documents
- form6-k.htm (6-K) — 20KB
- ex10-1.htm (EX-10.1) — 23KB
- 0001493152-24-041775.txt ( ) — 45KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: October 21, 2024 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer